Navigation Links
Another JDRF partner moves research forward with collaboration agreement for diabetes treatment
Date:6/18/2009

NEW YORK, June 18, 2009 The Juvenile Diabetes Research Foundation said today that for the fourth time in 18 months, one of its biotech partners has signed a collaboration agreement with a large pharmaceutical company to move research on type 1 diabetes into the final phases of trials.

According to JDRF, a leader in setting the agenda for diabetes research worldwide and the largest charitable funder and advocate of type 1 diabetes research, the development is the latest success in its innovative Industry Discovery and Development Partnership (IDDP) program, through which JDRF provides early stage research funding to biotech companies working on technologies and therapeutic candidates.

In the most recent success, JDRF industry partner Bayhill Therapeutics Inc., based in California, entered into a collaboration agreement with Genentech, Inc., a wholly owned member of the Roche Group, to further develop and potentially commercialize a novel antigen-specific immunotherapeutic designed to reverse the immune response that causes type 1 diabetes.

To date, JDRF has awarded more than $29 million in research funding to 25 companies through its IDDP program. JDRF supported the ongoing Bayhill clinical trial with an IDDP grant in October of 2008.

"We began the IDDP program to help small companies demonstrate proof-of-principle for innovative ideas and products to treat and cure type 1 diabetes, in order to attract funding for potential commercialization from large drug companies," said Alan J. Lewis, PhD, President and Chief Executive Officer of JDRF. "This latest agreement further demonstrates that the strategy is successful in accelerating the pace of research leading to a cure for diabetes."

Dr. Lewis noted that the development underscores JDRF's unique role helping to accelerate and translate research discoveries into cures and better treatment of type 1 diabetes and its complications. By supporting early stage research at small biotech companies, JDRF looks to lower the risk for larger pharmaceutical companies to create biotech partnerships and carry the products through expensive, late-stage trials and regulatory approvals. The goal, he said, is to bring cures and treatments for type 1 diabetes to market faster.

Other IDDP partners that have created similar agreements include: Tolerx, based in Massachusetts, which has joined with GlaxoSmithKline to develop an anti-CD3 antibody to preserve beta cell function in newly diagnosed patients; Maryland-based MacroGenics, which is developing a similar antibody with Lilly; and Canada's Transition Therapeutics, which has signed a commercialization agreement for a beta cell regenerative therapy with Lilly.

Bayhill's BHT-3021 compound is now in Phase I/II clinical trials supported by JDRF, is a plasmid encoding proinsulin designed to target specific pathogenic immune cells involved in the immune response of type 1 diabetes.


'/>"/>

Contact: William Ahearn
wahearn@jdrf.org
212-479-7531
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related biology news :

1. One species entire genome discovered inside anothers
2. Same gene protects from 1 disease, opens door to another
3. Another type of nanotube, a how-to guide to making bamboo-structured carbon nanotubes
4. For good or ill Ireland gains another mammal species
5. Ocean acidification -- another undesired side effect of fossil fuel-burning
6. Viral recombination another way HIV fools the immune system
7. Arctic ice on the verge of another all-time low
8. Another fisheries commission throws the science overboard in tuna decision, WWF says
9. Another reason to drink a nice cup of shade-grown joe
10. Cancer: Another step towards medication
11. Desert woodrats switch one dietary poison for another
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:2/28/2017)... 28, 2017 News solutions for biometrics, bag ... ... from 14 to 16 March, Materna will present its complete ... seamless travel is a real benefit for passengers. To accelerate ... their passenger touch point solutions to take passengers through the complete ...
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... March 22, 2017   Boston Biomedical , an ... designed to target cancer stemness pathways, today announced its ... as Chief Executive Officer, effective April 24, 2017. ... J. Li , M.D., FACP, who has led Boston ... Under his leadership, Boston Biomedical has grown from a ...
(Date:3/22/2017)... ... , ... Okyanos Cell Therapy has announced Tallahassee, FL will be the next ... Cell Therapy: The Next Phase in the Evolution of Medicine.” As the Bahamas’ first ... Therapy Act, Okyanos maintains a mission to help “no-option” patients and those with ...
(Date:3/22/2017)... ... March 21, 2017 , ... Aqua Design Innovations (ADI) has ... raising over $30,000 in the first 40 minutes of crowdfunding. EcoQube is a ... easy, and affordably, anywhere. , “Simply add fertilized water and in less than ...
(Date:3/22/2017)... ... March 21, 2017 , ... Functional near-infrared spectroscopy (fNIRS), an optical imaging tool ... way to track the brain’s response to acute pain in adults and infants. , ... ,” published today in the journal Neurophotonics , by SPIE, the international ...
Breaking Biology Technology: